Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004230 · ClinicalTrials.gov registry record · Phase 3
Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation
A Phase 3 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 3
- Development phase
- 35
- Enrollment target
NCT00004230 is a Phase 3 study that has completed, run by Northwestern University. The registered enrollment target is 35 participants.
The verdict
NCT00004230, a Phase 3 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 35 participants
- Enrollment target
Study Summary
RATIONALE: Captopril may protect the lungs from the side effects of bone marrow or stem cell transplantation. PURPOSE: Randomized phase III trial to determine the effectiveness of captopril to lessen the side effects in patients who are undergoing bone marrow or stem cell transplantation following chemotherapy and radiation therapy.
Interventions
- DRUG cyclophosphamide
- RADIATION radiation therapy
- PROCEDURE peripheral blood stem cell transplantation
- PROCEDURE autologous bone marrow transplantation
- DRUG captopril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 1999-10 |
| Est. Completion | 2002-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004230
The ClinicalTrials.gov registry entry for NCT00004230 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00004230 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004230 about?
NCT00004230 is a clinical study titled "Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation". RATIONALE: Captopril may protect the lungs from the side effects of bone marrow or stem cell transplantation. PURPOSE: Randomized phase III trial to determine the effectiveness of captopril to lessen the side effects in patients who are undergoing bone marrow or stem cell transplantation following ...
What is the current status of trial NCT00004230?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 35 participants. The study started on 1999-10. Estimated completion is 2002-03.
What interventions are being tested in trial NCT00004230?
The interventions under investigation include: cyclophosphamide (DRUG), radiation therapy (RADIATION), peripheral blood stem cell transplantation (PROCEDURE), autologous bone marrow transplantation (PROCEDURE), captopril (DRUG).
Who is sponsoring clinical trial NCT00004230?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.